XTalks

SEPTEMBER 4, 2024

Alnylam Pharmaceuticals announced promising results from its HELIOS-B Phase III clinical trial evaluating vutrisiran, an investigational RNA interference (RNAi) therapeutic for treating transthyretin amyloidosis with cardiomyopathy (ATTR-CM). As of March 2024, the FDA has approved six small interfering RNA (siRNA) therapies.

Trials 52

Trials RNA Protein Gene Editing 52

XTalks

JANUARY 8, 2024

“It’s important to make sure that with this increase in clinical trial complexity, we don’t make our trials overly burdensome to sites or patients,” says Markham. Keeping Trials on Track The preparation and analysis of samples within tight clinical trial timelines are crucial.

Clinical Trials 105

Clinical Trials Clinical Trials Trials Gene Therapy 105

XTalks

AUGUST 18, 2020

The study was funded by a clinical research agreement with the NBA and the players’ union – the National Basketball Players Association (NDG) – which together, contributed over $500,000 to fund the Yale study. This is significant because shortages of RNA extraction kits have been a recurrent issue since the beginning of the pandemic.

FDA Approval 90

FDA Approval Reagent RNA Genome 90

Cloudbyz

OCTOBER 15, 2020

For example, certain drugs like Favipiravir (RNA-dependent RNA polymerase inhibitor), Chloroquine, and Hydroxychloroquine gained enough media attention claiming it to be “game-changers.”

RNA 85

RNA Clinical Trials Clinical Trials Trials 85

pharmaphorum

APRIL 14, 2022

The two-day conference will bring you high-quality insights and industry connections on the latest clinical trial candidates and a platform for exchanging ideas for tackling the biggest challenge: DELIVERY.

RNA 52

RNA Clinical Trials Clinical Trials Life Science 52

XTalks

JUNE 18, 2024

XTALKS CLINICAL EDGE: Issue 2 — Elixirgen Therapeutics’ Interview Xtalks Clinical Edge is a magazine for clinical research professionals and all who want to be informed about the latest trends and happenings in clinical trials.

Protein 52

Protein RNA Genetics Gene Expression 52

Worldwide Clinical Trials

MAY 30, 2024

This approach is facilitated by developing ASOs and RNA interference (RNAi) therapies, which target the various molecular and genetic mechanisms contributing to ALS pathophysiology and disease progression. As we continue to explore current treatments and venture into new avenues of research, there lies hope for those affected by ALS.

Gene 204

Gene Clinical Trials Clinical Trials Gene Therapy 204

pharmaphorum

JUNE 28, 2022

Listen to case studies presenting on pre-clinical and clinical research in areas such as oncology and what can be learned for future clinical trials. Interested parties can register for the conference and workshop at: [link]. By attending the conference attendees will have the opportunity to.

RNA 52

RNA Development Engineer Clinical Trials 52

XTalks

JULY 14, 2022

Register for this free webinar for expert insights and an engaging discussion surrounding the utilization of electronic health record (EHR) data in clinical research and what the future might hold. Live and On-Demand: Tuesday, August 23, 2022, at 12pm EDT (5pm BST/UK). Gout is a significant therapeutic area for Horizon.

FDA Approval 105

FDA Approval Antibody Trials Drugs 105

XTalks

JUNE 4, 2024

In the past, the majority of drugs evaluated in the clinical pharmacology space were small molecules. Today, there’s been a shift towards more complex, large molecules or biologics like monoclonal antibodies, antibody-drug conjugates (ADCs) and advanced therapies like RNA-based treatments and cell and gene therapies.

Clinical Development 110

Clinical Development Development Clinical Trials Clinical Trials 110

Roots Analysis

AUGUST 28, 2022

As a result, industry and non-industry stakeholders, are on the lookout for advanced platforms that can simultaneously capture the arrangement of multiple biomolecules (DNA, RNA, proteins and others) with single-cell or subcellular resolution. 70+ spatial Genomics solutions are developed by industry and non-industry players.

Genome 52

Genome Genomics RNA Genome Project 52

The Pharma Data

NOVEMBER 16, 2020

It combines Moderna’s mRNA (messenger RNA) delivery platform with the stabilized SARS-CoV-2 spike immunogen (S-2P) developed by NIAID scientists. principal investigator of the NIAID-funded Infectious Diseases Clinical Research Consortium site at Baylor College of Medicine in Houston; Lindsey R. El Sahly, M.D., Baden, M.D.,

Clinical Trials 52

Clinical Trials Clinical Trials Vaccine Vaccination 52

XTalks

NOVEMBER 7, 2022

“Liquid biopsies have demonstrated promising activity in multiple clinical settings, but the great enthusiasm and expectations around them can be harmful if not adequately managed,” said Dr. El Mustapha Bahassi, PhD, Director, Clinical Laboratory Sciences, at the global clinical research organization (CRO) Medpace.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

The Pharma Data

SEPTEMBER 1, 2021

Molnupiravir (MK-4482/EIDD-2801) is an investigational, orally administered form of a potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. About Molnupiravir.

Trials 52

Trials Clinical Trials Clinical Trials RNA 52

Find Me Cure

OCTOBER 13, 2019

This Breast Cancer Awareness Month we’d like to talk about emerging areas in metastatic breast cancer treatment since clinical research has come so far in recent years. The team sequenced DNA and RNA from her tumour and from healthy tissue to find out which unique to her case mutations they needed to target.

Development 52

Development DNA Clinical Trials Clinical Trials 52

XTalks

AUGUST 18, 2023

Khanani, director of clinical research at Sierra Eye Associates, Reno, Nevada, in Iveric Bio’s news release. RELATED: Apellis’ Syfovre Approved as First Treatment for Geographic Atrophy Despite Uncertain Clinical Benefit What Is Geographic Atrophy? How Does Izervay Work?

FDA Approval 52

FDA Approval Drugs Clinical Trials Clinical Trials 52

STAT News

MARCH 6, 2023

Cambridge-based Moderna recently reported encouraging results from a study of another type of personalized cancer vaccine it developed with the pharmaceutical giant Merck; it uses messenger RNA technology to target advanced melanoma. But more work remains before personalized vaccines  can be greenlighted.

Vaccine 98

Vaccine Vaccination Drugs Clinical Trials 98

The Pharma Data

AUGUST 31, 2021

Over three years ~300,000 patients at high risk of a second cardiovascular event are expected to be treated with inclisiran, a small interfering RNA therapy administered as a 6-monthly maintenance dose ‡ , in the community setting. comments Jules Payne, Chief Executive at HEART UK, the cholesterol charity. About inclisiran.

Containment 52

Containment Production RNA Medicine 52

XTalks

AUGUST 30, 2022

Clinical research experts from the CRO Medpace shared insights about the operational and regulatory considerations for neuroscience trials with direct CNS administration. Such therapies may involve small interfering RNA (siRNA) or oligonucleotides in viral transfection platforms, large molecules and antibodies.

Trials 83

Trials Drug Delivery Drugs Gene 83

The Pharma Data

NOVEMBER 30, 2020

Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the primary efficacy analysis of the Phase 3 study of mRNA-1273 conducted on 196 cases confirms the high efficacy observed at the first interim analysis.

Vaccine 52

Vaccine Vaccination Medicine Clinical Trials 52

The Pharma Data

NOVEMBER 16, 2020

The study also included communities that have historically been under-represented in clinical research and have been disproportionately impacted by COVID-19. CAMBRIDGE, Mass.–(BUSINESS –(BUSINESS WIRE)–Nov. 16, 2020– Moderna, Inc. at large.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

The Pharma Data

OCTOBER 27, 2020

As a class, DARPin® therapeutics have demonstrated over years of clinical research a number of characteristics that enhance their profile as antiviral therapeutics for a global pandemic. ” Collaboration Terms and Share Subscription.

Development 40

Development Protein Manufacturing Medicine 40

The Pharma Data

JULY 29, 2021

At week 24, results showed that bulevirtide alone or in combination with peginterferon alfa-2a, is associated with a significant HDV RNA decline and improvements in biochemical disease activity. Gilead welcomed William Grossman, MD, PhD, as Senior Vice President, Oncology Clinical Research.

Sales 52

Sales Production FDA Approval Development 52

The Pharma Data

MARCH 9, 2021

Lenacapavir is a potential first-in-class capsid inhibitor that is designed to inhibit HIV replication as it interferes with the disassembly of the HIV capsid core, inhibits the role of capsid proteins during viral RNA/DNA translocation to the nucleus, and disrupts assembly of the capsid core.

Drugs 52

Drugs RNA Trials Development 52

AuroBlog - Aurous Healthcare Clinical Trials blog

DECEMBER 30, 2024

By trawling through databases of RNA sequences based on models of […] This growth of the gut’s wall hints at underlying pathways distinguishing beneficial regeneration from the rampant reproduction of a tumor.

RNA 246

RNA Clinical Trials Clinical Trials Clinical Research 246

Pharmaceutical Technology

FEBRUARY 20, 2023

This level of homogeneity within the clinical trial population may prevent the identification of variable therapy responses within population subgroups. We are poised to accelerate groundbreaking RNA therapy and vaccines for biopharma customers while becoming the reference lab for the cell and gene therapies of tomorrow.

Research 130

Research Clinical Trials Clinical Trials Trials 130

XTalks

FEBRUARY 27, 2025

Related: Iovebi (Inavolisib) Gains FDA Nod for PIK3CA-Mutated HR-Positive, HER2-Negative Breast Cancer Given the role of ESR1 , Bio-Techne launched a highly sensitive ESR1 mutation monitoring assay in December 2024 to track these mutations in ctDNA and exosomal RNA, helping to catch signs of resistance early on.

Trials 59

Trials HR Clinical Trials Clinical Trials 59

XTalks

FEBRUARY 11, 2025

Gene therapy has shown promise in treating cancers that are particularly difficult to manage such as neuroblastoma and Wilms tumor using CAR-T cell therapy, CRISPR-Cas9 gene editing and RNA-based interventions to target genetic drivers of disease.

Gene Therapy 66

Gene Therapy Clinical Trials Clinical Trials Trials 66

XTalks

FEBRUARY 20, 2025

Breakthroughs and Advances in Rare Disease Research Recent advances in rare disease research are ushering in transformative therapies for longstanding unmet needs. In hereditary angioedema (HAE), for example, donidalorsen an investigational RNA-targeted prophylactic treatment has demonstrated impressive efficacy.

Gene Therapy 59

Gene Therapy Gene Research Genetics 59

XTalks

SEPTEMBER 14, 2020

The company’s candidate vaccine, mRNA-1273, is a synthetic messenger RNA that encodes the stabilized SARS-CoV-2 spike protein. Below are some free webinars you can register for that have delved into the topic: Continuing Clinical Research Innovations After COVID-19. Addressing the Rapidly Evolving Vaccine Development Landscape.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92